Bilyana S.
- Country
- Bulgaria
- Department
- N/A
Research Overview
- Efficacy and safety of zenagamtide versus semaglutide in participants with overweight or obesity and type 2 diabetes
- Phase III Randomized, Double‑Blind Study of Elecoglipron versus Placebo for Glycemic Control in Adults with Type 2 Diabetes Mellitus on Basal Insulin
- Evaluation of Baxdrostat and Dapagliflozin on Chronic Kidney Disease Progression in Hypertensive Patients: A Randomized, Double-Blind, Active-Controlled Phase III Trial
Data & Insights
Has run more than one trial at 26 of 267 partner sites.
Specializations
Nephrology
The investigator specializes in treating patients with chronic kidney disease (CKD), focusing on innovative therapeutic approaches to slow disease progression and improve patient outcomes.
- Renal Function Assessment
- Glomerular Filtration Rate Monitoring
- Progressive Kidney Disease Management
Their work encompasses comprehensive evaluation of renal function and implementation of targeted therapeutic strategies.
Cardiovascular Medicine
The investigator has particular expertise in managing hypertension in patients with concurrent kidney conditions, exploring combination therapy approaches for blood pressure control.
- Blood Pressure Management
- Cardiovascular Risk Assessment
- Hypertension Treatment Optimization
Their focus includes developing effective treatment strategies for complex cardiovascular conditions in renal patients.
Therapeutic Innovation
The investigator evaluates novel therapeutic combinations for treating concurrent renal and cardiovascular conditions, with particular attention to medication efficacy and safety profiles.
- Combination Therapy Assessment
- Treatment Response Evaluation
- Patient Safety Monitoring
Their expertise extends to evaluating therapeutic interventions that address multiple clinical concerns simultaneously.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.